OQR300

OQR300 is a preclinical-stage therapeutic cancer vaccine being developed by the Austrian biotechnology company OncoQR ML GmbH. The drug is built upon the proprietary S-TIR™ (Specific Total Immune Remodeler) platform, which is designed to induce high-titer, specific antibody responses against clinically validated targets by bypassing immune tolerance. The S-TIR™ technology utilizes a modular design consisting of a generic 'warhead' module to activate the immune system and a disease-specific 'immunogen' module. While OncoQR describes the target of OQR300 as a '3rd blockbuster-clinically validated target,' the specific molecular target and the primary cancer indication have not been publicly disclosed.